David Krasne is a seasoned financial executive with extensive experience in various leadership roles across multiple companies. Currently serving as the Chief Financial Officer at Nanocan Therapeutics Corporation since January 2022, David also contributes as a co-founder and director at Sentire Medical Systems and KANNY, and is a co-founder and partner at RedNest Partners. Previous positions include co-founder and director at ExpertConnect, CEO and director at American Medical Forensic Specialists, and vice president at The Riverside Company. David's background features significant experience in private equity with Merrill Lynch Global Private Equity. Educational credentials include an MBA from UCLA Anderson School of Management and a BS in Finance and Accounting from Penn State University.